替米沙坦对高血压伴阵发性心房颤动患者房颤复发及C反应蛋白的影响

Effects of Telmisartan on Recurrence of Paroxysmal Atrial Fibrillation and Serum Levels of C Reaction Protein in Patients with Hypertension Combined with Paroxysm Atrial Fibrillation

目的观察替米沙坦对高血压伴阵发性心房颤动患者房颤复发及对左心房内径(LAD)、血清C反应蛋白(HsCRP)的影响。方法 2007年6月2008年12月阵发性房颤患者42例,随机分为替米沙坦组和常规治疗组各21例,分别于治疗前、治疗后12个月测定LAD、HsCRP水平,并随访治疗后12个月时房颤复发次数。结果替米沙坦组房颤复发次数及LAD、HsCRP水平均低于常规治疗组,两组比较,有统计学意义(P<0.05)。结论替米沙坦能抑制高血压伴阵发性房颤患者的左房重构,降低HsCRP水平,减少房颤复发。

Objective To explore the effects of Telmisartan on recurrence of paroxysmal atrial fibrillation （PAF）,left atrial direction（LAD）and serum levels of high sensitivity C reaction protein（HsCRP）in patients with hypertension combined with paroxysm atrial fibrillation.Methods A total of 42PAF patients from June 2007to December 2008were randomly divided into Telmisartan group and routine treatment group.Before the treatment and 12 months after the treatment,LAD and HsCRP were detected,and the recurrence times of atrial fibrillation were counted 12months after the treatment.Results The recurrence times of atrial fibrillation,and the levels of LAD and HsCRP were significant lower in Telmisartan group than that in the routine treatment group（P0.05）.Conclusion Telmisartan can reduce the recurrence of PAF and the levels of LAD and HsCRP.